Project Grant R01CA293029
Award Date
7/10/24
Completion Date
6/30/29
Dollars Obligated
$1.1M
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Davis, CA, USA
Similar Awards
This $238,722 federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research at the Sloan-Kettering Institute for Cancer Research to investigate the role of mutagenic DNA repair pathways in the persistence and acquired drug resistance of cancer cells. The key objectives are to: (1) study persistence mechanisms in BRCA1/2-mutant cancer cells treated with PARP inhibitors, (2) examine how mutagenic DNA repair via...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), provides $541,682 to The Trustees of Columbia University in the City of New York for a 5-year period from July 3, 2024 to June 30, 2029. The project aims to better understand the mechanisms responsible for the assembly of DNA repair domains in cancer cells and evaluate the consequences of these domains following treatment with chemotherapeutic drugs....
The Project Grant award R35CA293978, provided by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research), supports research to identify the mechanisms driving rapid evolution of cancer genomes. The $942,442 award to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA will fund investigations into two catastrophic mutational processes in cancer, chromothripsis and chromoplexy. The research aims to better understand the mechanisms of chromosome fragmentation, DNA...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) is funding research to elucidate the molecular mechanisms of DNA double-strand break repair by homologous recombination. The $445,000 award will support a 5-year research project led by the Dana-Farber Cancer Institute to use a novel Xenopus laevis egg extract system to study the regulation of key homologous recombination intermediates. This...
This National Cancer Institute (NCI) Project Grant award under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program provides $408,913 to the University of California Irvine from August 15, 2024 to July 31, 2029. The project investigates the mechanisms by which genes encoding ribosomal proteins are used as sensors for altered cellular chromosome content in fruit flies, a genetic model system. The research aims to define the molecular basis for cellular recognition and...
The National Cancer Institute (NCI) awarded a 5-year, $487,393 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Sloan-Kettering Institute for Cancer Research. The grant will fund research to determine the role of key proteins, including RAD52, HELQ, and POLQ, in backup DNA double-strand break repair pathways in homologous recombination-deficient (HRD) cancers. The research aims to identify additional proteins involved in these alternative repair...
This $2,556,071 Project Grant award was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) to The University of Texas Health Science Center at San Antonio. The award supports a collaborative research program focused on elucidating the mechanisms by which the BRCA1-BARD1 and BRCA2 tumor suppressors promote homologous recombination (HR) DNA repair, and how this is negatively regulated by the 53BP1 axis to favor the use of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $2,186,372 to the University of California, Irvine to support a new program project on "Tipping Points in Cancer". The 5-year project, starting April 1, 2025, will investigate fundamental biological processes underlying cancer initiation and progression, using advanced mouse models of chronic myeloid leukemia, melanoma, and triple-negative breast cancer. The project will...
This National Science Foundation (NSF) Biological Sciences (CFDA 47.074) Project Grant award of $246,424 supports research to define how human cells control the initiation and early steps of recombination at DNA double strand breaks. The project leverages novel methods to understand how cells choose different DNA repair mechanisms, with a focus on recombination, which maintains encoded genetic information. The research will address key questions around recombination activation, the role of the...
The National Cancer Institute (NCI) awarded a $581,381 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Sloan-Kettering Institute for Cancer Research in New York. The grant, spanning June 2025 to May 2030, supports research to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance. The research aims to better understand DNA damage repair pathways and how they contribute to genomic instability and...